Literature DB >> 497091

Pharmacokinetics and pharmacodynamics of warfarin at steady state.

P A Routledge, P H Chapman, D M Davies, M D Rawlins.   

Abstract

1 The relationship between warfarin dose, total and free plasma warfarin concentration, and anticoagulant effect was examined at several steady-state levels in fifteen patients during withdrawal of warfarin therapy. 2 Total plasma clearance was significantly correlated with the free fraction in plasma (r=0.955). 3 There was an age related decline in the dose of warfarin, and in the total and free plasma warfarin concentrations required to produce the same anticoagulant effect. However, neither total nor free plasma warfarin clearances varied with age. 4 Individual patients' log concentration-effect relationships were linear above a prothrombin ratio of 1.2 and there was a significant correlation (r=-0.586) between the slope and the free fraction of warfarin in plasma. It is suggested that plasma protein binding may reflect the interaction between warfarin and its effector site in the hepatocyte.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 497091      PMCID: PMC1429794          DOI: 10.1111/j.1365-2125.1979.tb01009.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Age as a determinant of sensitivity to warfarin.

Authors:  A M Shepherd; D S Hewick; T A Moreland; I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

2.  Tissue binding of drugs.

Authors:  M Gibaldi; P J McNamara
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

3.  Kinetics of warfarin absorption in man.

Authors:  A Breckenridge; M Orme
Journal:  Clin Pharmacol Ther       Date:  1973 Nov-Dec       Impact factor: 6.875

4.  Steady-state plasma concentrations of alprenolol in man.

Authors:  M D Rawlins; P Collste; M Frisk-Holmberg; M Lind; J Ostman; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

5.  Letter: Effect of plasma protein binding on elimination of warfarin.

Authors:  G Levy; A Yacobi
Journal:  J Pharm Sci       Date:  1974-05       Impact factor: 3.534

6.  Smoking and warfarin dosage.

Authors:  A A Mitchell
Journal:  N Engl J Med       Date:  1972-11-30       Impact factor: 91.245

7.  Protein binding of warfarin enantiomers in serum of humans and rats.

Authors:  A Yacobi; G Levy
Journal:  J Pharmacokinet Biopharm       Date:  1977-04

8.  Comparative pharmacokinetics of coumarin anticoagulants XXVIII: Predictive identification of rats with relatively steep serum warfarin concentration-anticoagulatnt response characteristics.

Authors:  A Yacobi; G Levy
Journal:  J Pharm Sci       Date:  1977-01       Impact factor: 3.534

9.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

10.  Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

Authors:  R J Lewis; W F Trager; K K Chan; A Breckenridge; M Orme; M Roland; W Schary
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

View more
  17 in total

1.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

Authors:  B Vadher; D L Patterson; M Leaning
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  The Smith Kline & French lecture 1987. Clinical pharmacology and the art of bespoke prescribing.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 4.  Physiological changes due to age. Pharmacodynamic changes of drug action and implications for therapy.

Authors:  P P Lamy
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

5.  Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin.

Authors:  Berit Packert Jensen; Paul Ken Leong Chin; Rebecca Lee Roberts; Evan James Begg
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

6.  Factors responsible for interindividual differences in the dose requirement of phenprocoumon.

Authors:  D Trenk; H Althen; E Jähnchen; T Meinertz; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Clinical pharmacology. Adverse reactions to drugs.

Authors:  M D Rawlins
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-21

Review 8.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  The influence of age, liver size and enantiomer concentrations on warfarin requirements.

Authors:  H Wynne; L Cope; P Kelly; T Whittingham; C Edwards; F Kamali
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

10.  The influence of prophylactic antibiotics on the warfarin anticoagulation response in the postoperative prosthetic cardiac valve patient. Cefamandole versus vancomycin.

Authors:  D M Angaran; V C Dias; K V Arom; W F Northrup; T E Kersten; W G Lindsay; D M Nicoloff
Journal:  Ann Surg       Date:  1984-01       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.